In light of the huge unmet need for novel antiviral strategies, an efficient solution is to identify common host factors hijacked by multiple viruses and repurpose approved drugs targeting these factors as broad-spectrum antivirals. The Khatri lab developed and validated a novel bioinformatics approach that is ideal for efficient identification of such candidate targets and antiviral drugs. By integrating meta-analysis of gene expression data and drug expression profiles we identified robust signatures of graft rejection and discovered drugs which improve graft survival. The Einav lab demonstrated feasibility of another repurposing approach. We discovered an Achilles' heel of infectious production of multiple viruses: a requirement for AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK), host kinases that regulate clathrin adaptor proteins pathways. We then discovered inhibitors of these targets, including approved anticancer drugs; sunifinib and eriotinib, and demonstrated potent activity against hepatitis C virus, dengue virus, and HIV. We hypothesize that: 1) meta-analysis of gene expression profiles from multiple viral infections can identify common host factors critical for infection, and approved drugs targeting these factors can be used as broad-spectrum antivirals. 2) AAK1 and GAK inhibitors represent a practical novel, host centered class of broad-spectrum antivirals with utility against viruses for which no treatment is available and resistant viruses.
In Aims 1 and 2 we will integrate gene expression data sets and perform meta-analysis to identify differentially expressed host factors across multiple viral infections. Existing drugs that may target these host factors will be predicted and their antiviral activity against multiple priority agents determined. Lead compounds will be further developed.
Aims 3 and 4 focus on preclinical development of approved drugs with anti-AAKI and GAK activity, already displaying broad-spectrum antiviral activity, as a clinical stage product ready for testing under an IND. We will obtain data sets supporting indications for sunitinib and eriotinib against infections with multiple priority pathogens and use best available authentic models to assess the in vivo feasibility and biological rationale of this approach.
These aims will integrate molecular virology, genomic, biochemical and pharmacological approaches. This project will contribute towards attainment of the multi-project center objectives by establishing a wide-spectrum repurposing pipeline against multiple NIAID Category A, B and C agents, from identifying new products at reduced time and cost to de-risking the clinical development of 2 approved drugs already showing promise.

Public Health Relevance

There is a critical need for more effective antiviral strategies. This proposal is aimed at improving human health by focusing on the identification and preclinical development of more effective, broad-spectrum antiviral strategies towards combating challenging viral infections with global implications via repurposing already approved drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109662-05
Application #
9631966
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Maric, Maja
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Haynes, Winston A; Tomczak, Aurelie; Khatri, Purvesh (2018) Gene annotation bias impedes biomedical research. Sci Rep 8:1362
Sweeney, Timothy E; Thomas, Neal J; Howrylak, Judie A et al. (2018) Multicohort Analysis of Whole-Blood Gene Expression Data Does Not Form a Robust Diagnostic for Acute Respiratory Distress Syndrome. Crit Care Med 46:244-251
Feinberg, Evan N; Sur, Debnil; Wu, Zhenqin et al. (2018) PotentialNet for Molecular Property Prediction. ACS Cent Sci 4:1520-1530
Robinson, Makeda; Schor, Stanford; Barouch-Bentov, Rina et al. (2018) Viral journeys on the intracellular highways. Cell Mol Life Sci 75:3693-3714
Schor, Stanford; Einav, Shirit (2018) Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs. ACS Infect Dis 4:88-92
Sweeney, Timothy E; Wynn, James L; Cernada, MarĂ­a et al. (2018) Validation of the Sepsis MetaScore for Diagnosis of Neonatal Sepsis. J Pediatric Infect Dis Soc 7:129-135
Wu, Zhenqin; Ramsundar, Bharath; Feinberg, Evan N et al. (2018) MoleculeNet: a benchmark for molecular machine learning. Chem Sci 9:513-530
Dudek, Amanda M; Pillay, Sirika; Puschnik, Andreas S et al. (2018) An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor. J Virol 92:
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Barouch-Bentov, Rina; Einav, Shirit (2018) Turning Up Your Nose for a Flaviviral Encephalitis Cure. Cell Host Microbe 23:427-429

Showing the most recent 10 out of 73 publications